BNTC Overview

Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

Wall Street analysts forecast BNTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTC is32.00 USD with a low forecast of 32.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Benitec Biopharma Inc revenue for the last quarter amounts to 0.00 USD, decreased

Benitec Biopharma Inc. EPS for the last quarter amounts to -0.26 USD, decreased -0.00

Benitec Biopharma Inc (BNTC) has 19 emplpoyees as of March 21 2026.

Today BNTC has the market capitalization of 377.21M USD.